1607P The impact of absolute neutrophil count on clinical trial participation in the United States von Adesunloye, B.

Volltext

Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts) von Bendell, J., Hubbard, J., O’Neil, B.H., Jonker, D., Starodub, A., Peyton, J., Pitot, H., Halfdanarson, T., Nadeau, B., Zubkus, J., Adesunloye, B., Edenfield, J., Li, Y.Z., Li, W., Grothey, A., Borodyansky, L., Li, C.J.

Volltext

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC von Durm, G., Althouse, S., Sadiq, A., Jalal, S., Jabbour, S., Zon, R., Kloecker, G., Fisher, W., Reckamp, K., Kio, E., Langdon, R., Adesunloye, B., Gentzler, R., Hanna, N.

Volltext

P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy von Durm, G., Althouse, S., Sadiq, A., Jalal, S., Jabbour, S., Zon, R., Kloecker, G., Williamson, M., Reckamp, K., Kio, E., Langdon, R., Adesunloye, B., Gentzler, R., Harb, W., Walling, R., Yeon, C., Koczywas, M., Hanna, N.

Volltext

Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer... von Schneider, B, Miller, KD, Badve, S, O'Neil, B, Helft, P, Chitambar, C, Falkson, C, Nanda, R, McCormick, M, Danso, M, Blaya, M, Langdon, R, Lippman, M, Paplomata, E, Walling, R, Thompson, M, Robin, E, Aggarwal, L, Shalaby, I, Canfield, V, Adesunloye, B, Lee, T, Daily, K, Ma, C, Erban, J, Radhakrishnan, N, Bruetman, D, Graham, M, Reddy, NA, Lynce, FC, Radovich, M

Volltext

LBA-003Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts) von Bendell, J, Hubbard, J, O'Neil, B H, Jonker, D, Starodub, A, Peyton, J, Pitot, H, Halfdanarson, T, Nadeau, B, Zubkus, J, Adesunloye, B, Edenfield, J, Li, Y Z, Li, W, Grothey, A, Borodyansky, L, Li, C J

Volltext

Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) von Huang, X., Ning, Y. M., Mulquin, M., Madan, R. A., Gulley, J. L., Kluetz, P. G., Adelberg, D., Arlen, P. M., Parnes, H. L., Adesunloye, B., Steinberg, S. M., Wright, J. J., Trepel, J. B., Chen, C., Bassim, C., Apolo, A. B., Figg, W. D., Dahut, W. L.

Volltext

Acute renal failure due to the herbal remedy CKLS von Adesunloye, Bamidele A.

Volltext

Orthodontic treatment need of children and adolescents with special healthcare needs resident in Ile-Ife, Nigeria von Akinwonmi, B. A., Kolawole, K. A., Folayan, M. O., Adesunloye, A. M.

Volltext

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer von Madan, Ravi A., Karzai, Fatima H., Ning, Yang‐Min, Adesunloye, Bamidele A., Huang, Xuan, Harold, Nancy, Couvillon, Anna, Chun, Guinevere, Cordes, Lisa, Sissung, Tristan, Beedie, Shaunna L., Dawson, Nancy A., Theoret, Marc R., McLeod, David G., Rosner, Inger, Trepel, Jane B., Lee, Min‐Jung, Tomita, Yusuke, Lee, Sunmin, Chen, Clara, Steinberg, Seth M., Arlen, Philip M., Gulley, James L., Figg, William D., Dahut, William L.

Volltext

The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from... von Shukla, Nikhil, Althouse, Sandra K., Sadiq, Ahad Ali, Jalal, Shadia Ibrahim, Jabbour, Salma K., Zon, Robin, Kloecker, Goetz H., Fisher, William B., Reckamp, Karen L., Kio, Ebenezer A., Langdon, Robert M., Adesunloye, Bamidele, Gentzler, Ryan D., Hanna, Nasser H., Durm, Greg Andrew

Volltext

Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN... von Durm, Greg Andrew, Althouse, Sandra K., Sadiq, Ahad Ali, Jalal, Shadia Ibrahim, Jabbour, Salma, Zon, Robin, Kloecker, Goetz H., Fisher, William B., Reckamp, Karen L., Kio, Ebenezer A., Langdon, Robert M., Adesunloye, Bamidele, Gentzler, Ryan D., Hanna, Nasser H.

Volltext

Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) von Adesunloye, Bamidele, Huang, Xuan, Ning, Yangmin M., Madan, Ravi A., Gulley, James L., Beatson, Melony, Kluetz, Paul Gustav, Adelberg, David E., Arlen, Philip M., Parnes, Howard L., Mulquin, Marcia, Steinberg, Seth M., Wright, John Joseph, Trepel, Jane B., Dawson, Nancy Ann, Chen, Clara, Bassim, Carol, Apolo, Andrea Borghese, Figg, William Douglas, Dahut, William L.

Volltext

Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) von Adesunloye, Bamidele, Huang, Xuan, Ning, Yangmin M., Madan, Ravi A., Gulley, James L., Beatson, Melony, Kluetz, Paul Gustav, Adelberg, David, Arlen, Philip M., Parnes, Howard L., Mulquin, Marcia, Steinberg, Seth M., Wright, John Joseph, Trepel, Jane B., Dawson, Nancy Ann, Chen, Clara, Apolo, Andrea Borghese, Figg, William Douglas, Dahut, William L.

Volltext